Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)

Molidustat is a next-generation hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, developed to stimulate endogenous erythropoietin (EPO) production. In feline medicine, Molidustat is increasingly explored off-label to support the management of non-regenerative anaemia associated with Chronic Kidney Disease (CKD) in cats.

By promoting physiologic red blood cell production rather than replacing EPO externally, Molidustat offers a novel, oral approach for long-term anemia support when used under strict veterinary guidance.

Molidustat inhibits prolyl hydroxylase enzymes, stabilising HIF-α (Hypoxia-Inducible Factor) under normal oxygen conditions. This leads to:

• Increased endogenous erythropoietin (EPO) production

• Enhanced iron metabolism and utilisation

• Stimulation of erythropoiesis in bone marrow

Unlike injectable recombinant EPO, Molidustat promotes a more physiologic and sustained erythropoietic response.